Epidemiological Forecast of Bronchiolitis, 2030 – Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan – ResearchAndMarkets.com

0
11
Epidemiological Forecast of Bronchiolitis, 2030 – Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan – ResearchAndMarkets.com


DUBLIN–(COMMERCIAL THREAD) –The report “Bronchiolitis – Epidemiological forecasts until 2030” has been added to ResearchAndMarkets.com offer.

The total of 7MM of incident bronchiolitis in 2020 was 8,026,904. The incident bronchiolitis population in 7MM is expected to increase at a CAGR of 0.01% for the 2018-2030 study period.

This report “Bronchiolitis-Epidemiology Forecast – 2030” provides an in-depth understanding of bronchiolitis, historical and predicted epidemiology in the US, EU5 (Germany, Spain, Italy, France and UK) and Japan .

Epidemiology of bronchiolitis

The Bronchiolitis Epidemiology division provides historical and current patient pool information and forecast trend for all seven major countries. It helps to recognize the causes of current and projected trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the pool of diagnosed patients along with their trends and assumptions.

Main conclusions

The disease epidemiology covered in the report provides the epidemiology of historical and predicted bronchiolitis, segmented into incident bronchiolitis and bronchiolitis incidence by etiologies. The report includes incident symptoms of bronchiolitis in the United States, EU5 countries (Germany, France, Italy, Spain and United Kingdom) and Japan from 2018 to 2030.

Epidemiology of bronchiolitis by country

The epidemiology segment also provides data and epidemiological findings for bronchiolitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Scope of the report

  • The Bronchiolitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment regimens.

  • Bronchiolitis Epidemiology Report and Model provides insight into global risk factors and trends for bronchiolitis in the US, EU5 (Germany, Spain, Italy, France and UK) and Japan

  • The report provides an overview of the historical and projected bronchiolitis patient pool in the US, EU5 (Germany, Spain, Italy, France and UK) and Japan

  • Report Helps Recognize Growth Opportunities In 7MM Regarding Patient Population

  • Report assesses risk and burden of disease and highlights unmet need for bronchiolitis

  • The report provides the segmentation of the epidemiology of bronchiolitis by prevalent cases of bronchiolitis in the US, EU5 (Germany, Spain, Italy, France and UK) and Japan.

  • The report provides the segmentation of the epidemiology of bronchiolitis by prevalent cases of severity-specific bronchiolitis in the US, EU5 (Germany, Spain, Italy, France and UK) and Japan.

Main topics covered:

1. Key information

2. Presentation of the report

3. Overview of the Bronchiolitis Market at a Glance

3.1. Market share (%) Distribution of bronchiolitis in 2018

3.2. Market share (%) Distribution of bronchiolitis in 2030

4. Executive summary of bronchiolitis

5. Background and overview of the disease

5.1. introduction

5.2. Sign and symptoms

5.3. Classification

5.4. Causes

5.5. Pathophysiology

5.6. Pathophysiology of RSV bronchiolitis

5.7. Clinical manifestation

5.8. Diagnostic

6. Epidemiology and patient population

6.1. Main conclusions

6.2. Total population of 7 MM of patients with bronchiolitis

6.3. Hypothesis and justification

6.4. United States

6.4.1. Incidence of bronchiolitis

6.4.2. Incidence of bronchiolitis by etiologies

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. UK

6.10. Japan

7. Treatment and management

8. Guidelines for diagnosis and treatment

8.1. American Academy of Pediatrics (AAP) 2014 Guidelines

8.2. Lignes directrices 2015 du National Institute for Health and Care Excellence (NICE)

8.3. National Health Service (NHS) Guidelines 2018

9. Patient journey

10. Case report

11. Organizations contributing to bronchiolitis

12. Emerging therapies

12.1. MV130 : Immunotech

12.1.1. Description of the drug

12.1.2. Clinical development

12.1.3. Information on clinical trials

12.1.4. Safety and efficiency

12.1.5. Product profile

12.2. Nirsevimab : Sanofi/AstraZeneca

12.3. Vaccin VRS F : Novavax

12.4. MK-1654 : Merck

13. Dormant therapies

13.1. MK-0476 : Merck

13.1.1. Description of the drug

13.1.2. Clinical development

13.1.3. Information on clinical trials

13.1.4. Product profile

14. Interrupted treatments

14.1. Suptavumab : Regeneron

14.1.1. Description of the drug

14.1.2. Product development activity

14.1.3. Clinical development

14.1.4. Information on clinical trials

14.1.5. Product profile

15. KOL Views

16. Market drivers

17. Market barriers

18. Analyse SWOT

19. Unmet needs

20. Annex

For more information on this report, visit https://www.researchandmarkets.com/r/ieqa0c

LEAVE A REPLY

Please enter your comment!
Please enter your name here